Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation

DOI: 10.1158/2159-8290.CD-RW2019-185 Published February 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: DT2216, a proteolysis-targeting chimera (PROTAC), effectively targets BCL-XLfor degradation.

  • Concept: Unlike other drugs targeting cancer-promoting BCL-XL, DT2216 spares platelets.

  • Impact: DT2216 is promising for BCL-XL-dependent cancers; other tissue-specific PROTACs may be of interest.

Overexpression of antiapoptotic proteins in the B-cell lymphoma (BCL) family is a common feature of many cancers. In particular, BCL extra large (BCL-XL) is a target of interest due to its high expression in solid tumors and some leukemias, but development of drugs targeting BCL-XL has been thwarted by thrombocytopenia. Building on ABT263, a small-molecule BCL2/BCL-XL inhibitor that exhibits this dose-limiting toxicity, Khan, Zhang, Lv, and colleagues developed a cell-selective proteolysis-targeting chimera (PROTAC), dubbed DT2216, with not only reduced platelet toxicity, but also improved antitumor efficacy relative to ABT263. This PROTAC was designed with a BCL2/BCL-XL–binding moiety derived from ABT263 joined via an empirically optimized linker to a ligand of the Von Hippel-Lindau (VHL) E3 ligase, which is not highly expressed in platelets. DT2216 was confirmed to cause BCL-XL–specific ubiquitination and subsequent proteasome-mediated degradation while sparing other BCL family members despite the ABT263-derived moiety's affinity for BCL2; this may be due to an inability of DT2216 to form a stable ternary complex with BCL2 and VHL in cells. In mouse experiments using T-cell acute lymphoblastic leukemia (T-ALL) xenografts, therapeutically equivalent doses of ABT263 and the PROTAC DT2216 exhibited marked differences in their effects on platelets, with DT2216 producing far lower platelet toxicity. The antitumor efficacy of DT2216 was associated with its ability to induce degradation of BCL-XL, consistent with the notion that DT2216 acts as a BCL-XL–specific PROTAC in vivo. Additionally, DT2216 exhibited synergistic effects with BCL-family inhibitors and conventional chemotherapy in cell line–derived xenograft models dependent on multiple BCL-family proteins as well as in a T-ALL patient-derived xenograft model that was highly chemotherapy resistant. In summary, the authors have developed a novel drug targeting the elusive BCL-XL with improved efficacy and reduced toxicity compared to its predecessor, although further work would be needed to optimize the dose. Further, this work demonstrates how PROTACs that bind tissue-specific E3 ligases can be used to target the drugs to the desired sites, limiting their toxicity in other tissues.

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 2019;25:1938–47.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation
Cancer Discov February 1 2020 (10) (2) 174; DOI: 10.1158/2159-8290.CD-RW2019-185

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation
Cancer Discov February 1 2020 (10) (2) 174; DOI: 10.1158/2159-8290.CD-RW2019-185
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Drug Development

  • A Therapeutic GFRAL Antibody Blocks Cancer-Linked Cachexia in Mice
  • New Method Enables Design of Protein Drugs That Covalently Bind Targets
  • PP2A Activators Stabilize PP2A Complexes with Differing Specificities
Show more Drug Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement